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The incidence of multiple drug resistant tuberculosis
(MDR-TB) is increasing worldwide, limiting the effec-
tiveness of conventional drug therapies. Fluoroquinolone
antibiotics may offer an effective drug treatment option
for susceptible and MDR-TB.
OBJECTIVE: To review clinical and non-clinical evi-
dence of the efficacy, safety, and product characteristics
of fluoroquinolones with regard to their potential use in
the treatment of pulmonary TB.
METHODS: This review focused on fluoroquinolones
that have been approved for marketing in the US. Char-
acteristics assessed included: dosage; dosing frequency; ap-
proved indications; treatment duration; pharmacodynamics/
pharmacokinetics; adverse events; drug interactions; mu-
tagenic and teratogenic potential; structure-function relation-
ships; long-term use; Cmax and AUC ratios for M. tuberculo-
sis; and efficacy against susceptible and MDR-TB as reported
from in vitro, animal model, and clinical assessments. Infor-
mation was taken from the Physician’s Desk Reference, Drug
Facts and Figures, product monographs, medical literature in-
cluding clinical trial reports, the Food and Drug Adminis-
tration’s Center for Drug Evaluation and Research (CDER)
approval packages for fluoroquinolones, and expert opinion.
RESULTS: The earliest introduced fluoroquinolones,
such as norfloxacin and enoxacin, are least likely to be
useful in treating TB, due to low clinical efficacy. Trova-
floxacin is also ineffective against TB, and has undesir-
able adverse effects. Some fluoroquinolones, such as
sparfloxacin, offer efficacy against TB, but also have
problematic adverse effects. Ciprofloxacin and ofloxacin
are moderately effective against TB, and have generally
favorable characteristics. Levofloxacin has shown effi-
cacy in vitro and in animal models, as well as favorable
drug interaction and adverse event profiles, but human
efficacy is inconclusive. Moxifloxacin and gatifloxacin
may offer similar profiles to levofloxacin, but clinical
trial efficacy data is insufficient to draw conclusions.
CONCLUSIONS: While no one fluoroquinolone pos-
sesses all of the desirable characteristics for a new pulmo-
nary TB therapy, there are a number of candidates that
may have clinical efficacy and generally favorable profiles.
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In 1997, there were approximately eight million new ac-
tive cases of tuberculosis but only two percent of cases
were in established market economies. There is a need for
new drugs that could shorten treatment times but a con-
cern about return on investment (ROI) in this disease
area.
OBJECTIVE: To measure the ROI for a tuberculosis
drug development program.
METHODS: ROI may be measured by computing the net
present value of the estimated costs and revenue streams.
An EXCEL spreadsheet model was prepared that had a
25-year time horizon, starting as the molecule entered
Phase 1 trials. The model included costs for clinical trials,
non-clinical development, manufacturing development,
cost of goods, and sales and marketing. Revenues were
estimated for each year after launch assuming three years
to peak sales, five years at peak sales, and a 20 year
patent life from the start of Phase 1. A discount rate of 12
percent was used to compute the net present value. Alter-
native cost scenario models were based on whether time
from start of Phase 1 to launch was 10 years (normal) or
seven years (rapid) and whether clinical trials were con-
ducted in the US or Uganda. Alternative revenue scenar-
ios were also modeled.
RESULTS: Total discounted costs were $13.9 million,
$21.3 million, $9.0 million, and $13.7 million for the
normal US, rapid US, normal Uganda, and rapid Uganda
scenarios and medium revenue stream. Total discounted
revenue for the medium revenue assumption was $28.0
million at normal development and $46.6 million at
rapid development. Net present values ranged between
$6.8 million and $162.1 million for the 12 combinations
of costs and revenues modeled.
CONCLUSIONS: Drugs for tuberculosis will have a pos-
itive return on investment if molecules can be identified
when they enter Phase 1 of development.
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OBJECTIVES: To assess the compliance with antibiotic
prophylaxis practices and identify the factors associated
with practice variations in total hip replacement (THR)
surgery.
METHODS: We carried out a retrospective survey of
medical records in the orthopedic surgery department in
a 2,200-bed university hospital. A sample of 416 patients
undergoing THR from January 1999 to December 2000
was drawn. Practice conformity was evaluated based on
French guidelines for good clinical practice concerning
antibiotic prophylaxis in orthopedic surgery. Five major
criteria were used: antibiotic prophylaxis use; choice of
molecule; dosage at first injection; time between first in-
jection and incision; total duration. A multilevel hierar-
chical logistic regression analysis was performed using
global conformity as the dependant variable.
RESULTS: Among the 386 medical records analyzed, an-
tibiotic prophylaxis was used in 366 (95%) interventions.
The choice of molecule was consistent with the reference
for 258 (70%) patients. Among patients receiving a rec-
ommended molecule, dosage and timing of first injection
were consistent respectively for 98% (290/296) and 80%
